Immunogenicity Summit 2010

Conference Proceeding CD Now Available
  • Speaker Presentations
  • Poster Abstracts
  • and More!

 

 

Steve SwansonDeveloping a Risk-Based Approach to Immunogenicity Assessment

Steven J. Swanson, Ph.D., Executive Director, Clinical Immunology, Amgen, Inc.

 

 

Richard GarmanInduction of Immune Tolerance to Therapeutic Proteins

Richard Garman, Ph.D., Scientific Director, Immunology R&D, Genzyme Corp.

 

 

Jack RaghebVisible and Subvisible Aggregates: Assessing their Potential Impact on Immunogenicity

Jack A. Ragheb, M.D., Ph.D., Principal Investigator, Laboratory of Immunology, Division of Therapeutic Proteins, Office of Biological Products, CDER, FDA

 

 

Update on the Biosafe White Paper for Pre-Clinical Immunogenicity

Lakshmi Amaravardi, Ph.D., Director, Pre-clinical & Clinical Development, Biogen Idec, Inc.

October 18

1: Technical Advice on Assay Development, Validation and Sample Analysis*

2: Development of Cell-Based Neutralizing Antibody Assays*

Course Leaders

Arno Kromminga, Ph.D., CEO, Immunology, IPM BIOTECH

Lakshmi Amaravardi, Ph.D., Director, Pre-clinical & Clinical Development Sciences, Biogen Idec, Inc.

Shobha Purushothama, Ph.D., Scientist, Bioanalytical R&D, Pfizer, Inc.

 

Click here for more information regarding these short courses.


* Separate Registration Required, please see registration page for details.

 



Following inaugural success, we present our Second Annual Immunogenicity Summit: A case study-rich event covering advances in immunogenicity assays and their application to pre-clinical and clinical development. Also includes risk assessment, regulatory and white paper guidance, factors causing immunogenicity and means of predicting and controlling it. Excellent networking and discussion opportunities.

Keynote Speakers

Steven J. Swanson, Ph.D., Executive Director, Clinical Immunology, Amgen, Inc.
Richard Garman, Ph.D., Scientific Director, Immunology R&D, Genzyme Corp.
Jack A. Ragheb, M.D., Ph.D., Principal Investigator, Laboratory of Immunology, Division of Therapeutic Proteins, Office of Biological Products, CDER, FDA
Lakshmi Amaravardi, Ph.D., Director, Pre-clinical & Clinical Development, Biogen Idec, Inc.


Featured Presentations
Matthew Baker, Ph.D., Chief Scientific Officer, R&D, Antitope Ltd.
Deborah Finco, Ph.D., Senior Principal Scientist, Immunotoxicology, Pfizer, Inc.
Valerie Quarmby, Ph.D., Principal Scientist & Director, BioAnalytical Technologies & Strategies, Genentech, Inc.
Wytske Kingma, M.D., S.V.P., Global Medical Affairs, Genzyme Corp.
Stephen Lee, Ph.D., Associate Professor, Biomedical Engineering, Ohio State University

Distinguished Faculty List

Margot O’Toole, Ph.D., Director, Translational Medicine, Pfizer, Inc.
Donald Bennett, Ph.D., Director, Biostatistics, Biogen Idec, Inc.
Satish K. Singh, Ph.D., Research Fellow, Biotherapeutics Pharmaceutical Sciences, Pfizer, Inc.
Michele Fiscella, Ph.D., Associate Director, Clinical Immunology, Human Genome Sciences
Patrick Liu, Ph.D., Associate Director, Development Sciences Management, Genentech, Inc.
Joao A. Pedras-Vasconcelos, Ph.D., Visiting Associate, Therapeutic Proteins CBER, FDA
Sebastian Spindeldreher, Ph.D., Deputy Head, Bioanalytics, Novartis Pharma A.G.
Kay-Gunner Stubenrauch, Ph.D., Senior Scientist, Pharma Research, Bioanalytics, Roche Diagnostics
Masanori Onda, M.D., Ph.D., Laboratory of Molecular Biology, NCI/NIH
Josefin-Beate (Josi) Holz, Ph.D., Chief Medical Officer, Drug Development, Ablynx nv
Frank J. Carr, Ph.D., Director, Biologics Research, Antitope Ltd.
Arno Kromminga, Ph.D., CEO, Immunology, IPM BIOTECH 
Katherine A. High, M.D., Investigator, Howard Hughes Medical Institute; William H. Bennett Professor of Pediatrics, University of Pennsylvania School of Medicine; Director, Center for Cellular and Molecular Therapeutics, The Children’s Hospital of Philadelphia
Jaya Goyal, Ph.D., Principal Investigator, Clinical Science and Technology, Biogen Idec, Inc.
David W. Scott, Ph.D., Professor of Surgery and of Microbiology and Immunology, University of Maryland School of Medicine
Eric D. Foehr, Ph.D., Director, Bioanalytical R&D, Biomarin Pharmaceuticals, Inc.
Philippe Stas, M.B.A., Head, Applied Protein Services, Lonza Biologics; Head, Algonomics NV
Matthew Seefeldt, Ph.D.,Vice President, Research, BaroFold, Inc.
Christoph Giese, Ph.D., Director, Probiogen GmbH
Mikael Sørud, M.Sc., Director, Regulatory Affairs, Novo Nordisk A/S
Bernard Maillere, Ph.D., Head, Immunochemistry, Institute of Biology and Technologies, CEA
Ralf Hess, Ph.D., Principal Consultant, Early Stage Drug Development, Parexel (Tentative)


By Series:
By Region: